Profile: Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

1,730.00GBp
11:35am EDT
Price Change (% chg)

3.00p (+0.17%)
Prev Close
1,727.00p
Open
1,722.00p
Day's High
1,742.00p
Day's Low
1,720.00p
Volume
94,224
Avg. Vol
223,339
52-wk High
1,832.51p
52-wk Low
1,010.48p

Search Stocks
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates in three business segments: Branded, Injectables, and Generics. The majority of its operations are in the Middle East and North Africa region, the United States and Europe. The Company’s operations span over 45 countries and focuses on a range of therapeutic areas. The Company’s other businesses primarily consists of Arab Medical Containers Ltd, a manufacturer of pharmaceutical packaging; and International Pharmaceutical Research Center Ltd, which conducts bio-equivalency studies, and the chemicals division of Hikma Pharmaceuticals Ltd. In July 2014, the Company acquired the assets of the United States generic injectables business, Bedford Laboratories (Bedford) from Ben Venue Laboratories, Inc.

Company Address

Hikma Pharmaceuticals PLC

13 Hanover Square
LONDON   ENG   W1S 1HW
P: +4420.73992760
F: +4420.73992761

Search Stocks